Show simple item record

dc.contributor.authorThompson, Marcos.
dc.contributor.authorMarciano, Sebastián.
dc.contributor.authorDirchwolf, Melisa.
dc.contributor.authorEt al.
dc.date.accessioned2023-08-14T16:33:55Z
dc.date.available2023-08-14T16:33:55Z
dc.date.issued2021-11
dc.identifier.citationAnn Hepatol . 2021 Nov-Dec;25:100344es
dc.identifier.issn2659-5982
dc.identifier.urihttps://riu.austral.edu.ar/handle/123456789/2270
dc.descriptionDisponible en: https://www.sciencedirect.com/science/article/pii/S1665268121000430?via%3Dihubes
dc.description.abstractAbstract Introduction and objectives: Failures at any step in the hepatocellular carcinoma (HCC) surveillance process can result in HCC diagnostic delays and associated worse prognosis. We aimed to estimate the prevalence of surveillance failure and its associated risk factors in patients with HCC in Argentina, considering three steps: 1) recognition of at-risk patients, 2) implementation of HCC surveillance, 3) success of HCC surveillance. Methods: We performed a multi-center cross-sectional study of patients at-risk for HCC in Argentina seen between10.01.2018 and 10.30.2019. Multivariable logistic regression analysis was used to identify correlates of surveillance failure. Results: Of 301 included patients, the majority were male (74.8%) with a mean age of 64 years old. At the time of HCC diagnosis, 75 (25%) patients were unaware of their diagnosis of chronic liver disease, and only 130 (43%) patients were under HCC surveillance. Receipt of HCC surveillance was significantly associated with follow-up by a hepatologist. Of 119 patients with complete surveillance, surveillance failure occurred in 30 (25%) patients. Surveillance failure was significantly associated with alpha fetoprotein ≥20 ng/mL (OR 4.0, CI 95% 1.43-11.55). Conclusions: HCC surveillance failure was frequent in all the evaluated steps. These data should help guide strategies to improve the implementation and results of HCC surveillance in our country. Keywords: Alpha fetoprotein; Cirrhosis; Failure; Liver cancer; Screening. Copyright © 2021 AEDV. Published by Elsevier España, S.L.U. All rights reserved.es
dc.language.isoenes
dc.publisherElsevieres
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAlpha fetoprotein.es
dc.subjectCirrhosis.es
dc.subjectFailure.es
dc.titleFailure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practicees
dc.typeArticlees


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional